Welcome to our dedicated page for Sonnet Biotherapeutc Hldng news (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet Biotherapeutc Hldng stock.
Sonnet BioTherapeutics Holdings Inc. develops immunotherapeutic biologic drugs for oncology using its FHAB Fully Human Albumin-Binding platform. The platform uses a fully human single-chain antibody fragment designed to bind human serum albumin and transport large-molecule therapies toward tumor and lymphatic tissue, supporting constructs that include cytokines, peptides, antibodies and vaccines.
Company news centers on clinical and regulatory updates for targeted oncology programs, including SON-1010 or IL-12-FHAB in solid tumors and platinum-resistant ovarian cancer, as well as scientific conference presentations, shareholder voting matters, financing activity, capital-structure disclosures and governance developments.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) reported significant advancements in its drug pipeline and announced a successful warrant repricing and exchange, generating gross proceeds of $10.5 million. During Q1 2020, Sonnet completed preclinical studies showing promising results in tumor reduction with its FHAB-derived drug candidates. The company is negotiating a licensing deal for its IL-6 assets for diabetic neuropathy, potentially earning $500,000 upfront and up to $36 million in milestone payments. As of June 30, 2020, Sonnet has $3.1 million cash on hand.